In the treatment of mild-to-moderate asthma, fewer systemic effects are seen with hydrofluoroalkane-propelled fluticasone propionate (HFA-FP) than with the chlorofluorocarbon formulation (CFC-FP) at 1000 g/d, but there is no added airway benefit in increasing the dose beyond 500 g/d, according to a report in the August issue of Chest. On the other hand, an increased benefit observed CFC-FP at doses greater than 500 g/d is offset by an increase in systemic effects.
In a randomized, placebo-controlled, crossover study, Dr. Brian J. Lipworth and colleagues from the University of Dundee, UK, studied the therapeutic ratio of HFA and CFC formulations of fluticasone propionate in 18 subjects with mild-to-moderate asthma.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!